These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22947594)

  • 1. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate.
    Einarson TR; Hemels ME; Nuamah I; Gopal S; Coppola D; Hough D
    Ann Pharmacother; 2012 Oct; 46(10):1322-30. PubMed ID: 22947594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
    Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
    Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
    Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW
    Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprolactinaemia during treatment with paliperidone.
    Skopek M; Manoj P
    Australas Psychiatry; 2010 Jun; 18(3):261-3. PubMed ID: 20429680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.
    Gopal S; Lane R; Nuamah I; Copenhaver M; Singh J; Hough D; Bach M; Savitz A
    CNS Drugs; 2017 Sep; 31(9):797-808. PubMed ID: 28660406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
    J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
    Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving.
    Edwards NC; Muser E; Doshi D; Fastenau J
    J Med Econ; 2012; 15(4):623-34. PubMed ID: 22332706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic-induced hyperprolactinemia.
    Bostwick JR; Guthrie SK; Ellingrod VL
    Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: Preliminary findings of the first 3 months.
    Karslioğlu EH; Kolcu Z; Karslioğlu Nİ; Çayköylü A
    Hum Psychopharmacol; 2022 May; 37(3):e2827. PubMed ID: 34787912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
    Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey.
    Johnsen E; Kroken RA; Abaza M; Olberg H; Jørgensen HA
    J Clin Psychopharmacol; 2008 Dec; 28(6):686-90. PubMed ID: 19011438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
    Park YM; Lee SH; Lee BH; Lee KY; Lee KS; Kang SG; Lee HY; Kim W
    Psychiatry Res; 2016 May; 239():184-9. PubMed ID: 27010188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of paliperidone-palmitate-induced tardive dyskinesia.
    Lally J; Byrne F; Walsh E
    Gen Hosp Psychiatry; 2013; 35(2):213.e5-7. PubMed ID: 22703608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
    Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
    Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects.
    Si T; Su Y; Liu Y; Zhang H; Li H; Rui Q; Shu L
    Hum Psychopharmacol; 2014 Mar; 29(2):203-10. PubMed ID: 24590546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.